Penn Neurodegeneration Genomics Center

Seminars and Workshops

PENN NEURODEGENERATION GENOMICS CENTER: SEMINAR SERIES
May 15, 2018 - 3:00pm - John Morgan Building — Class of 62' Auditorium 
Ophir Shalem, PhD  —  “CRISPR based on functional genomics for studying protein quality control and neurodegeneration”


PENN NEURODEGENERATION GENOMICS CENTER: SEMINAR SERIES
May 3, 2018 - 2:00pm - John Morgan Building — Class of 62' Auditorium 
Judith A.J. Steen, PhD  —  “Systems Biology of Tauopathy”


PENN NEURODEGENERATION GENOMICS CENTER: SEMINAR SERIES
November 29, 2017 - 1:30pm - John Morgan Reunion Auditorium
Bradley T. Hyman, MD, PhD  —  “Heterogeneity, tau, and rates of progression of Alzheimer's”


PENN NEURODEGENERATION GENOMICS CENTER: SEMINAR SERIES
May 17, 2017 - 2:00pm - John Morgan Reunion Auditorium
Jennifer E. Phillips-Cremins, PhD  —  “3D Epigenome Reconfiguration in the Developing Mammalian Brain”


PENN NEURODEGENERATION GENOMICS CENTER: SEMINAR SERIES
April 5, 2017 - 2:00pm - John Morgan Reunion Auditorium
Justin Ichida, PhD —  "Identification of therapeutic targets for ALS using chemical and genetic screens on patient-derived neural cultures"  
Abstract: Neurodegenerative disease is one of the only causes of human morbidity that continues to increase in lethality. Decades of drug development efforts suggest that new therapeutic targets and a better understanding of disease processes will be necessary for curative treatments. To this end, we have employed iPSC technology to develop a phenotypic screen for ALS using C9ORF72 and sporadic patient neural cultures. We have identified new targets that when perturbed by small molecules can rescue the neurodegenerative processes in C9ORF72 ALS patient motor neurons. In addition, we have identified new genetic mutations that may contribute to sporadic ALS, some of which converge mechanistically with targets identified by our small molecule screens on C9ORF72 patient motor neurons. Combined with mechanistic studies in iPSC-derived cultures, post-mortem tissue, and mice, these studies elucidate ALS disease processes and point to new therapeutic targets that may modify disease progression in humans.


PENN NEURODEGENERATION GENOMICS CENTER: SEMINAR SERIES
February 6, 2017 - 2:00pm - John Morgan Reunion Auditorium
Alison Goate, DPhil — "Common and Rare Variant Risk Factors in AD implicate Microglial Function"

 
 

© The Trustees of the University of Pennsylvania | Site best viewed in a supported browser. | Site Design: PMACS Web Team.